![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Vlad Ratziu, Mary Rinella, Brent Neuschwander-Tetri, Eric Lawitz, Douglas Denham, ZeidKayali, AasimSheikh, Kris Kowdley, TaddeseDesta, Magdy Elkhashab, Jeffery DeGrauw, Alaa Ahmad, Kajal Larson,
Ty McClure, Nathalie Adda
![0904201](../images/090420/090420-16/0904201.gif)
![0904202](../images/090420/090420-16/0904202.gif)
![0904203](../images/090420/090420-16/0904203.gif)
![0904204](../images/090420/090420-16/0904204.gif)
![0904205](../images/090420/090420-16/0904205.gif)
![0904206](../images/090420/090420-16/0904206.gif)
![0904207](../images/090420/090420-16/0904207.gif)
![0904208](../images/090420/090420-16/0904208.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|